24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
CAPELIEVA 500MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | CAPELIEVA 500MG |
|---|---|
| Composition | Capecitabine Tablets IP 500mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (12 x 10 Tab) |
| Country of Origin | India |
CAPELIEVA 500MG (Capecitabine Tablets IP 500mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
CAPELIEVA 500 MG (Capecitabine Tablets IP 500 mg) is a prescription anticancer medicine containing Capecitabine 500 mg, an oral chemotherapy medication widely used for the treatment of various types of cancer, including colorectal cancer, breast cancer, gastric cancer, and other advanced solid tumors. Capecitabine belongs to a class of medicines known as antimetabolites, which work by interfering with the growth and multiplication of cancer cells.
Capecitabine is considered a prodrug, meaning it is converted inside the body into 5-Fluorouracil (5-FU), a well-established anticancer agent. This conversion occurs more actively within tumor tissues, helping target cancer cells while reducing exposure to healthy tissues. As a result, CAPELIEVA 500 MG offers the convenience of oral administration while delivering the proven benefits of fluoropyrimidine-based cancer therapy.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. CAPELIEVA 500 MG helps slow or stop this process by disrupting DNA synthesis in rapidly dividing cancer cells, thereby reducing tumor growth and progression.
The medicine is frequently prescribed as a standalone therapy or in combination with other chemotherapy agents, targeted therapies, or radiation treatment depending on the type and stage of cancer.
CAPELIEVA 500 MG is commonly prescribed for:
One of the key advantages of Capecitabine is that it allows patients to receive chemotherapy treatment at home under the supervision of their oncologist, reducing the need for frequent hospital-based infusions.
Manufactured according to strict pharmaceutical quality standards, CAPELIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Capecitabine therapy require regular medical monitoring, including blood tests, liver and kidney function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven clinical effectiveness and convenient oral administration, CAPELIEVA 500 MG remains an important component of modern cancer treatment worldwide.
CAPELIEVA 500 MG (Capecitabine Tablets IP 500 mg) is primarily used in the treatment and management of several types of cancer.
The medicine is widely prescribed for patients diagnosed with colon or rectal cancer.
Capecitabine may be used when colorectal cancer has spread to other organs.
The medicine is commonly used in certain stages of breast cancer treatment.
Doctors may prescribe Capecitabine for advanced breast cancer that has spread beyond the breast.
The medicine may be included in treatment plans for stomach cancer.
Capecitabine is used in selected gastrointestinal malignancies.
The medicine is frequently combined with other anticancer therapies for enhanced treatment outcomes.
Capecitabine helps support disease control and treatment continuity.
Capecitabine belongs to a class of medicines known as Antimetabolite Chemotherapy Agents.
CAPELIEVA works by:
This targeted metabolic action helps control tumor growth and improve treatment outcomes.
Like all medicines, CAPELIEVA 500 MG may cause side effects in some patients. The occurrence and severity of side effects vary among individuals.
Diarrhea is one of the most frequently reported side effects.
Patients may experience mild to moderate nausea.
Some individuals may develop vomiting during treatment.
Weakness and tiredness are commonly reported.
Reduced appetite may affect nutritional intake.
Redness, swelling, pain, or peeling of the palms and soles may occur.
Inflammation or sores inside the mouth may develop.
Some patients may experience stomach pain or digestive disturbances.
The medicine may affect blood cell production in certain patients.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of CAPELIEVA 500 MG (Capecitabine Tablets IP 500 mg) should always be determined by a qualified oncologist.
Dosage depends on the specific cancer being treated.
Treatment is often calculated based on the patient’s body size.
Kidney and liver function may influence dosage decisions.
Doctors may adjust therapy according to effectiveness and tolerance.
Dosage may vary when used alongside other anticancer medicines.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of colorectal cancer, breast cancer, gastric cancer, and other selected solid tumors.
Capecitabine is an oral chemotherapy medicine that is converted into 5-Fluorouracil (5-FU) inside the body.
Yes. Capecitabine is an oral chemotherapy medication used to treat various cancers.
Yes. It is an oral medicine that allows patients to receive treatment at home under medical supervision.
Hand-Foot Syndrome is a common side effect that may cause redness, swelling, pain, or peeling of the palms and soles.
Yes. Routine blood tests and clinical evaluations are important throughout treatment.
Yes. It is frequently combined with other chemotherapy agents, targeted therapies, or radiation treatment as part of comprehensive cancer care.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology treatment.